Vlado Perkovic's Publications

About Vlado Perkovic's Publications

Board Member
  • MBBS,
  • PhD,
  • FASN,
  • FRACP

  • The prevalence of chronic kidney disease in Australian primary care: analysis of a national general practice dataset

    Unknown Date published:

  • A meta-analysis of GFR slope as a surrogate endpoint for kidney failure

    Nature Medicine Date published:

  • Cardiorenal protective effects of canagliflozin in CREDENCE according to glucose lowering

    BMJ Open Diabetes Research & Care Date published:

  • #3807 HEART FAILURE IN ASCEND-ND AND ASCEND-D

    Nephrology Dialysis Transplantation Date published:

  • #4333 A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF BION-1301 IN ADULTS WITH IGA NEPHROPATHY

    Nephrology Dialysis Transplantation Date published:

  • Kidney protection with canagliflozin: A combined analysis of the randomized CANVAS program and CREDENCE trials

    Diabetes, Obesity and Metabolism Date published:

  • The sodium-glucose cotransporter-2 inhibitor canagliflozin does not increase risk of non-genital skin and soft tissue infections in people with type 2 diabetes mellitus: A pooled post hoc analysis from the CANVAS Program and CREDENCE randomized double-blind trials

    Diabetes, Obesity and Metabolism Date published:

  • Glucocorticoids for IgA nephropathy-pro

    Kidney International Date published:

  • Effects of newer kidney protective agents on kidney endpoints provide implications for future clinical trials

    Kidney International Date published:

  • Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

    The Lancet Date published:

  • Glycemic Control and Effects of Canagliflozin in Reducing Albuminuria and eGFR: A Post Hoc Analysis of the CREDENCE Trial

    Clinical Journal of the American Society of Nephrology Date published:

  • Effects of canagliflozin on cardiovascular and kidney events in patients with chronic kidney disease with and without peripheral arterial disease: integrated analysis from the CANVAS Program and CREDENCE trial

    Diabetes, Obesity and Metabolism Date published:

  • Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial

    American Journal of Kidney Diseases Date published:

  • IgA Nephropathy Patient Baseline Characteristics in the Sparsentan PROTECT Study

    Kidney International Reports Date published:

  • WCN23-0069 EFFICACY AND SAFETY OF REDUCED-DOSE ORAL METHYLPREDNISOLONE IN IGA NEPHROPATHY: THE TESTING TRIAL

    Kidney International Reports Date published:

  • WCN23-0412 EFFECT OF IPTACOPAN ON PROTEINURIA AND COMPLEMENT BIOMARKERS OVER TIME IN IgA NEPHROPATHY

    Kidney International Reports Date published: